ABEO (Abeona Therapeutics) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABEO Abeona Therapeutics Inc ABEO
32 GF Score
Price $7.45
! 8 Warning Signs
View Full Analysis

What is Abeona Therapeutics 3-Year EBITDA Growth Rate?

Abeona Therapeutics ABEO +2.90% 32 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates ABEO with a GF Score™ of 32/100. The stock has 8 warning signs investors should review. Among 1,131 Biotechnology companies, Abeona Therapeutics ranks worse than 88417.24% on this metric.

Abeona Therapeutics's EBITDA per Share for the three months ended in Mar. 2026 was $-0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Abeona Therapeutics was 70.60% per year. The lowest was -34.90% per year. And the median was 9.30% per year.

Abeona Therapeutics  (NAS:ABEO) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Abeona Therapeutics 3-Year EBITDA Growth Rate Related Terms

ABEO vs RCKT, UPB, PALI: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Abeona Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's 3-Year EBITDA Growth Rate falls into.


ABEO
32GF Score
Abeona Therapeutics Inc ABEO
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abeona Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Abeona Therapeutics (ABEO) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Abeona Therapeutics and its competitors. According to the industry distribution chart, Abeona Therapeutics ranks #999999 out of 1131 companies in the Biotechnology industry.
Is Abeona Therapeutics' 3-Year EBITDA Growth Rate too high?
Abeona Therapeutics' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Abeona Therapeutics ranks #999999 out of 1131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abeona Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' 3-Year EBITDA Growth Rate compare to RCKT and UPB?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #999999 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Abeona Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Abeona Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abeona Therapeutics's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Abeona Therapeutics' overall GF Score™ is 32/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abeona Therapeutics Business Description

Other Exchanges 0H7R:UKPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
32GF Score

Get the complete analysis for ABEO

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price